There is substantial evidence implicating both inflammation and mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS) pathogenesis. We investigated the therapeutic effects of cyclooxygenase 2 (COX-2) inhibitors both alone and in combination with creatine in the G93A transgenic mouse model of ALS. Oral administration of either celecoxib or rofecoxib significantly improved motor performance, attenuated weight loss and extended survival. The administration of COX-2 inhibitors significantly reduced prostaglandin E2 levels at 110 days of age. The combination of creatine with COX-2 inhibitors produced additive neuroprotective effects and extended survival by approximately 30%. The COX-2 inhibitors significantly protected against depletion of anterior horn motor neurons and creatine with COX-2 inhibitors showed greater protection than COX-2 inhibitors alone. These results suggest that combinations of therapies targeting different disease mechanisms may be a useful strategy in the treatment of ALS.
Amyotrophic lateral sclerosis (ALS) is one of the most common adult-onset neurodegenerative diseases. A major advance in studying the disease pathogenesis was the discovery of mis-sense mutations in the gene coding for Cu/Zn superoxide dismutase 1 (SOD1) in a subset of patients with autosomal dominant inherited ALS (Rosen et al. 1993) . This led to the development of transgenic mouse models of ALS, which has spurred research into pathogenetic mechanisms (Gurney 1994; Wong et al. 1995) . Elucidating the mechanism by which the SOD1 mutations lead to disease remains challenging. Nevertheless, the transgenic mouse models have suggested that both mitochondrial dysfunction and inflammatory mechanisms contribute to disease pathogenesis. Mitochondrial swelling and vacuolization are amongst the earliest pathological features found in two strains of transgenic ALS mice with SOD1 mutations (Wong et al. 1995; Gurney et al. 1998 ). An increase in cyclooxygenase 2 (COX-2) message, protein and prostaglandin E2 (PGE2) levels was found in both transgenic ALS mice as well as in post-mortem brain tissue, cerebrospinal fluid and serum from sporadic ALS patients (Almer et al. 2001 Ilzecka 2003) .
We previously showed that creatine administration, which can compensate for mitochondrial dysfunction, exerts neuroprotective effects and extends survival in transgenic mouse models of ALS (Klivenyi et al. 1999) . Others have shown that COX-2 inhibitors protect motor neurons in vitro and extend survival or delay disease onset in transgenic mouse models of ALS (Drachman and Rothstein 2000; Drachman et al. 2002; Pompl et al. 2003) . In the present study we examined whether creatine could exert additive neuroprotective effects when administered with either celecoxib or rofecoxib, the two COX-2 inhibitors presently approved for use in man.
Materials and methods

Mice
Transgenic mice with the G93A mutation of the human SOD1 gene (G1H/1) mutation [B6SJL-TgN (SOD1-G93A) 1 Gur] were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and were bred locally with female B6SJL mice (Jackson Laboratories). The offspring were genotyped by PCR assay of DNA obtained from tail tissue. The mice were fed either a diet supplemented with 2% creatine (Avicena, Inc., Cambridge, MA, USA), 0.005% rofecoxib (Vioxx, Merck & Co., Inc., Whitehouse Station, NJ, USA), 0.012% celecoxib (Celebrex; Pfizer, Inc., New York, NY, USA) or the combination of 2% creatine and rofecoxib or celecoxib, starting at 30 days of age. Twelve mice fed unsupplemented diets served as a control. The number of G93A mice in each treatment group was 11-13. An additional six to seven mice in each group were studied histologically. The experimental groups were balanced by sex. All animal experiments were carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the local animal care committee.
Behavioral testing (rotorod)
Mice were given 5 days to become acquainted with the rotorod apparatus (Columbus Instruments, Columbus, OH, USA). Testing then began with the mice trying to stay on a rod that was rotating at 12 r.p.m. and the time when they fell off the rod was used as the measure of competence on this task. The maximum score was 300 s, each mouse was given two trials and the best result was recorded. Mice were tested every other day until they could no longer perform the task. The mice were weighed once a week.
Survival
G93A transgenic mice initially showed a resting tremor that progressed to gait abnormalities, paralysis of the hindlimbs, then to paralysis of the forelimbs and finally to complete paralysis. Mice were killed when they could no longer roll over within 10 s of being pushed on their side. This time point was used as the time of death.
Prostaglandin E2 tissue content
The levels of PGE2 in brain and spinal cord tissues were measured by enzyme-linked immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's instructions. Briefly, frozen cerebral cortex and spinal cords were homogenized in 0.1 M phosphate-buffered saline (containing 1 mM EDTA and 10 lM indomethacin). After homogenization, samples were spiked with 10 000 d.p.m. of 5,6,8,11,12,14,15(n) [ 3 H] PGE2 (specific activity 151 Ci/mmol; Amersham, Piscataway, NJ, USA), mixed and centrifuged at 10 000 g for 25 min. Supernatant fluids were removed, mixed with an equal volume of ethanol and centrifuged at 1500 g. The supernatant fluids were diluted with 50 mM acetate buffer and purified through an affinity column (Cayman Chemical) according to the manufacturer's instructions. The purified samples were evaporated, redissolved in enzyme-linked immunoassay buffer and applied to 96-well plates pre-coated with goat anti-mouse IgG and incubated with PGE2 monoclonal antibody and recovery tracer for 18 h at 4°C. The plate was rinsed five times with washing buffer and developed using Ellman's reagent for 60-90 min at room temperature with gentle shaking. The PGE2-specific concentration was determined spectrophotometrically and calculated by plotting the standard percentage B/B0 (% sample or standard Bound/ Maximum Bound) versus PGE2 concentration (in pg/mL) using PGE2 analysis software and expressed in pg/mg of tissue.
Histological evaluation G93A transgenic mice and N1029 mice (110 days old, n ¼ 6 or 7 per group) were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and perfused transcardially with ice-cold 0.9% NaCl followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The spinal cords were removed, post-fixed for 2 h in the same fixative and then cryoprotected in 30% sucrose overnight at 4°C. Serial-cut coronal tissue sections (50 lm thick) from lumbar 1-4 segments were cut using a cryostat and mounted onto gelatincoated slides. The sections were stained for Nissl substance with cresyl violet and examined under a Nikon Eclipse E600 microscope (Morrell Instruments, Melville, NY, USA). The total number of Nissl-stained neurons was estimated within the ventral horn of 20 serial-cut tissue sections using the optical fractionator method in the Stereo Investigator (version 4.35) software program (Microbrightfield, Burlington, VT, USA). Cell counts were made within an area demarcated by a horizontal line drawn through the central canal and encompassing the ventral horn of the gray matter to include layers 7-9. Data are expressed as the mean ± SEM. Immunocytochemistry was carried out with a COX-2 specific antibody (Cayman Chemical).
Statistical analysis
Statistical comparisons were by one-way ANOVA or by repeated measures ANOVA followed by Newman-Keuls post-hoc test.
Results
Oral administration of 2% creatine, 0.005% rofecoxib and 0.012% celecoxib in the diet resulted in significant improvements in the survival of G93A mice compared with the survival of mice fed an unsupplemented diet (Fig. 1) . The mean survival of mice on supplemented diets increased from 126.1 ± 2.6 to 151.4 ± 2.1 days with creatine (p < 0.0001), to 152.3 ± 4.2 days with rofecoxib (p < 0.0001), to 150.2 ± 4.4 days with celecoxib (p < 0.0001), to 162.1 ± 4.0 days with creatine/celecoxib (p < 0.0001) and to 165.1 ± 4.2 days with creatine/rofecoxib (p < 0.0001). An additive neuroprotective effect was seen in the combined groups compared with the creatine-, celecoxib-and rofecoxib-treated groups (p < 0.05). Survival was extended by 25 days with creatine, 26 days with rofecoxib, 24 days with celecoxib, 36 days with the creatine/celecoxib combination and 39 days with the creatine/rofecoxib combination.
The treated mice had significantly better motor performance from 99 to 134 days of age than mice fed unsupplemented diets (Fig. 2) . Additive improvement was seen in the combination groups of creatine/celecoxib or creatine/rofecoxib as compared with creatine, celecoxib and rofecoxib alone. The COX-2 inhibitors and creatine also delayed weight loss, shown by a significantly higher weight in the treated animals from 115 days of age. All compounds and combinations were almost equally effective in delaying weight loss (Fig. 3) .
We determined whether the observed changes in survival were associated with detectable alteration of COX-2 enzymatic activity, as assessed by PGE2 content (Fig. 4) . We found that the spinal cord and cerebral cortex content of PGE2 was significantly increased in G93A mice at 110 days of age (p < 0.001). Treatment with COX-2 inhibitors in the Fig. 2 Effects of 2% creatine, 0.005% rofecoxib and 0.012% celecoxib and their combination on rotarod performance in G93A transgenic mice. CRT, 2% creatine diet; celecoxib, 0.012% celecoxib; rofecoxib, 0.005% rofecoxib diet; CRT/celec, 2% creatine and 0.012% celecoxib diet; CRT/rofec, 2% creatine and 0.005% rofecoxib diet. *p < 0.05 compared with controls; **p < 0.05 compared with CRT, celecoxib; #p < 0.05 compared with CRT-, celecoxib-and rofecoxib-treated mice. Fig. 3 Effects of 2% creatine, 0.005% rofecoxib and 0.012% celecoxib and their combination on body weight of G93A transgenic mice. Mean body weight in grams. Control, control (unsupplemented diet); CRT, 2% creatine diet; celecoxib, 0.012% celecoxib diet; rofecoxib, 0.005% rofecoxib diet; CRT/celec, 2% creatine and 0.012% celecoxib diet; CRT/rofec, 2% creatine and 0.005% rofecoxib diet. *p < 0.05 compared with controls; **p < 0.01 compared with controls. Fig. 1 Effects of 2% creatine, 0.005% rofecoxib and 0.012% celecoxib and their combination on survival in G93A transgenic mice. (a) Cumulative probability of survival. (b) Mean survival. Co, control (unsupplemented diet); CRT, 2% creatine diet; celecoxib, 0.012% celecoxib diet; rofecoxib, 0.005% rofecoxib diet; CRT/celec, 2% creatine and 0.012% celecoxib diet; CRT/rofec, 2% creatine and 0.005% rofecoxib diet. *p < 0.001 compared with controls; **p < 0.05 compared with CRT-, celecoxib-and rofecoxib-treated mice. Fig. 4 Effects of 2% creatine, 0.005% rofecoxib and 0.012% celecoxib and their combination on prostaglandin E2 (PGE2) levels in (a) the cerebral cortex and (b) the spinal cord of G93A transgenic mice at 110 days of age. #p < 0.01 compared with control; **p < 0.001 compared with untreated G93A mice. The groups studied from left to right were controls, controls (celecoxib), controls (rofecoxib), G93A, G93A (celecoxib), and G93A (rofecoxib).
transgenic mice significantly reduced the PGE2 levels (p < 0.001). We also examined numbers of Nissl-stained neurons at 110 days of age (Fig. 5) . Stereological analysis of Nissl-stained sections of the lumbar spinal cord revealed an attenuation of ventral horn neuronal loss in mice that received creatine and COX-2 inhibitors (Fig. 5) . Untreated G93A mouse spinal cord sections showed a significant neuronal loss compared with N1029 controls overexpressing wild-type SOD (p < 0.001). Creatine supplementation increased the number of surviving motoneurons compared with unsupplemented G93A mice; however, the result was not significant, probably due to the small number of mice examined. Both rofecoxib and celecoxib provided significant neuroprotection compared with untreated transgenic mice (p < 0.001 and p < 0.01, respectively). Creatine in combination with either rofecoxib or celecoxib produced additive neuroprotective effects (p < 0.001 and p < 0.01, respectively, vs. untreated G93A mice). Lastly, we examined the localization of COX-2 in the G93A mice at 110 days of age. As shown in Fig. 6 , there was a marked increase in COX-2 immunoreactivity in motoneurons in the G93A mice and, to a lesser extent, microglia which was not seen in controls.
Discussion
There is substantial evidence implicating both mitochondrial dysfunction and inflammatory mechanisms in ALS pathogenesis. Evidence for inflammation comes from studies in both transgenic mouse models and human post-mortem studies showing a robust glial reaction and microglial activation (Hirano 1996; Schiffer et al. 1996; Hall et al. 1998) The pro-inflammatory factors interleukin (IL)-6 and IL-1b are increased in the cerebrospinal fluid and spinal cord, respectively, in ALS patients (Li et al. 2000; Sekizawa et al. 1998) . Interleukin-1b, tumor necrosis factor-a and inducible nitric oxide synthase (iNOS) levels are increased in transgenic mouse models of ALS (Ghezzi et al. 1998; Almer et al. 1999; Li et al. 2000; Elliott 2001 ). Inhibition of IL-1b activation slows disease progression in one transgenic mouse model of ALS (Friedlander et al. 1998) ; however, in another model, an absence of IL-1b had no effect (Nguyen et al. 2001) . Transcription profiling of the spinal cords of mice with the G93A SOD1 mutation showed up-regulation of tumor necrosis factor-a, CD68 and caspase 1 mRNA at 11 weeks of age prior to motor neuron death (Yoshihara et al. 2002) . Markers of microglial activation, including CD36, MAC-1, cathepsin-S, B 2 microglobulin, C10C-alpha and AG C1Q-beta, are increased at 90 and 120 days of age (Olsen et al. 2001) , IL-b, IL-1b and IL-1RA are increased at 80 days and multiple caspase and death receptor components are increased at 120 days of age (Hensley et al. 2002) .
Cyclooxygenase 2 is expressed and up-regulated in glial cells by cytokines such as IL-1b, tumor necrosis factor-a and lipopolysaccharide (Cao et al. 1995; O'Banion et al. 1996) . However, COX-2 is primarily expressed in neurons following excitotoxic lesions, apoptotic neuronal death and cerebral ischemia (Adams et al. 1996; Tocco et al. 1997; Ho et al. 1998; Planas et al. 1999; Iadecola et al. 2001) . Cyclooxygenase 2 contributes to neuronal cell death both in vitro and in vivo. Overexpression of COX-2 can activate cell cycle genes, which may contribute to apoptotic cell death (Mirjany et al. 2002) . Cyclooxygenase catalyzes the formation of prostaglandins, which involves reduction of the hydroperoxide resulting in the generation of free radicals. Mice overexpressing COX-2 show increased vulnerability to kainic acid and have elevated lipid peroxidation (Kelley et al. 1999) . Neuronal death mediated by N-methyl-D-aspartate is diminished by COX-2 inhibitors in primary neuronal cultures (Hewett et al. 2000) . Transgenic mice which are deficient in COX-2 show reduced susceptibility to focal ischemia and to N-methyl-D-aspartate neurotoxicity . Cyclooxygenase 2 inhibitors also protect against MPTP (Teismann and Ferger 2001) .
In ALS spinal cord there is a sevenfold up-regulation of COX-2 mRNA and a 3.8-fold increase in protein levels (Yasojima et al. 2001) . In the spinal cord of the G93A SOD1 transgenic ALS mice there is a marked up-regulation of COX-2 mRNA in early symptomatic and end-stage illness (Almer et al. 2001) . Furthermore, immunostaining is markedly increased in neurons and, to a lesser extent, in glia of the anterior horn of the spinal cord. In the present study, we confirmed this finding which suggests that neuronal COX-2 may play a role in the cell death observed in these mice. Measurements of COX-2 protein by western blot and catalytic activity as assessed by PGE2 content show increases which are most marked at end-stage illness in the G93A SOD1 transgenic mice (Almer et al. 2001) . We also observed a significant increase in PGE2 levels in both the cerebral cortex and spinal cord of G93A SOD1 mice.
There is a significant increase in PGE2 levels in postmortem spinal cord and CSF of sporadic ALS patients (Almer et al. 2001 . Cyclooxygenase 2 inhibitors block the production of PGE2 which inhibits glutamate reuptake and could exacerbate ALS in which excitotoxic mechanisms have been implicated (Bezzi et al. 1998) . Cyclooxygenase 2 inhibitors also inhibit lipopolysaccharide-induced increases in tumor necrosis factor-a which can stimulate astrocytic glutamate release Bezzi et al. 2001) . Inhibition of COX-2 protects motor neurons in an organotypic model of ALS (Drachman and Rothstein 2000) and administration of the COX-2 inhibitor celecoxib increased survival in G93A SOD1 mice (Drachman et al. 2002) . Mitochondrial dysfunction also occurs in ALS. Mutant SOD1 is localized to the intermembrane space of mitochondria (Higgins et al. 2002) . Mitochondrial vacuolization and swelling are amongst the earliest pathological features in two strains of transgenic ALS mice with SOD1 mutations (Gurney 1994; Wong et al. 1995) . The mitochondrial vacuolization correlates well with a rapid deterioration in motor performance (Kong and Xu 1998) and is accompanied by reductions in the activities of electron transport enzymes and by ATP depletion which may contribute to cell death (Browne et al. 2001) . Creatine can increase brain phosphocreatine concentrations and protect against mitochondrial dysfunction (Hemmer and Walliman 1993) . Phosphocreatine serves as a direct energy source for reuptake of glutamate into synaptic vesicles and impaired glutamate uptake has been implicated in the pathogenesis of sporadic ALS Andreassen et al. 2001; Wendt et al. 2002) . We previously showed that creatine administration produces dose-dependent improvements in survival, motor performance and loss of spinal cord motor neurons in G93 SOD1 mice with a maximal effect of about 18% with 2% creatine in the diet (Klivenyi et al. 1999) .
Therefore, in the present study we examined whether administration of the COX-2 inhibitors celecoxib or rofecoxib either alone or in combination with creatine could exert neuroprotective effects in the G93A SOD1 transgenic mouse model of ALS. We found that both celecoxib and rofecoxib exert significant neuroprotective effects when administered alone. The effects of the two COX-2 inhibitors were similar, resulting in increases in survival of 20.6 and 19.8%, respectively. These results are consistent with a recent report by Drachman et al. (2002) . Both agents significantly prolonged survival, delayed weight loss and improved motor performance. Furthermore, they significantly protected against motor neuron loss in the anterior horn of the lumbar spinal cord. Consistent with a previous report PGE2 levels were significantly increased in the G93A ALS transgenic mice at 110 days of age and treatment with COX-2 inhibitors significantly reduced these increases (Almer et al. 2001) . The finding of an increase in brain PGE2 levels is consistent with recent reports of the vulnerability of cranial motor neurons as well as loss of substantia nigra neurons in G93A SOD transgenic mice (Kostic et al. 1997; Klivenyi et al. 1999; Haenggeli and Kato 2002) . Another COX-2 inhibitor, nimesulide, also inhibited increases in PGE2 in G93A SOD1 transgenic mice (Pompl et al. 2003) Creatine alone produced a significant increase in survival of 19.8%, consistent with our previous study.
When creatine and COX-2 inhibitors were administered together they produced additive neuroprotective effects. Creatine with celecoxib improved survival by 28.6% and creatine with rofecoxib improved survival by 30.9%. This is the best improvement in survival thus far achieved by a pharmacological treatment. Furthermore, the two agents together produced additive effects on motor performance. They also showed better neuroprotection against cell loss of the anterior horn motor neurons in the lumbar spinal cord at 110 days of age. A caveat about creatine, however, is that a recent clinical trial in ALS patients failed to show a benefit (Groeneveld et al. 2003) . This raises the possibility that either dosing is critical or that findings in this transgenic mouse model of familial ALS may not be predictive of therapeutic effects in sporadic ALS. This is less likely to be the case with COX-2 inhibitors as PGE2 levels are increased in sporadic ALS patients (Almer et al. 2001 Ilzecka 2003) .
The results, therefore, provide further evidence that coadministration of therapeutic agents targeting different disease mechanisms may be beneficial in the treatment of ALS. It was recently shown that coadministration of minocycline with creatine produces additive neuroprotective effects with a maximal improvement in survival of 25% (Zhang et al. 2003) . Furthermore, another recent study showed additive neuroprotective effects of riluzole, minocycline and nimodipine (Kriz et al. 2003) . The finding that coadministration of two therapeutic agents targeting different disease mechanisms can exert additive protective effects is similar to our recent observations in transgenic mouse models of Huntington's disease (Ferrante et al. 2002) . Both creatine and COX-2 inhibitors are safe and well tolerated in man, and therefore can be readily examined in clinical trials (Fitzgerald and Patrono 2001) These results, therefore, suggest that administration of combinations of therapeutic agents targeting different disease mechanisms may be a useful strategy for the treatment of ALS.
